#114 $CORT FDA Shock The Approval That Never Came

Dive into the Corcept Therapeutics $CORT controversy as we break down a securities class action tied to biotech approvals, FDA setbacks, and alleged misleading statements حول relacorilant. This episode is for investors, traders, and anyone following biotech stocks, clinical trials, and market volatility. Expect deep dives, case analysis, and insights into FDA risk, insider selling, and stock crashes.

Visit ZLK.com for more info.

Add our WhatsApp Channel

We’re not lawyers or accountants, so don’t take this as legal or financial advice.